drugset
drugset / Trial / NCT06718946

Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

NCT06718946 ↗

Phase 0 Recruiting 38 enrolled Fudan University
NaSequentialOpen-labelTreatment

Summary

This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of Intravenous Administration of IDOV-SAFETM in patients with advanced solid tumors.

Timeline

Start
2024-12-10
Primary completion
2025-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IDOV-SAFE Unknown 3e+08 unknown Intravenous
Subject IDOV-SAFE Unknown 7e+08 unknown Intravenous
Subject IDOV-SAFE Unknown 1e+09 unknown Intravenous
Subject IDOV-SAFE Unknown 3e+09 unknown Intravenous
Subject IDOV-SAFE Unknown 7e+09 unknown Intravenous
Subject IDOV-SAFE Unknown 1e+10 unknown Intravenous
Subject IDOV-SAFE Unknown 3e+10 unknown Intravenous

Indications

cancer